BioNxt Solutions Inc.

BioNxt Solutions Inc. researches, develops, manufactures, and sells next-generation drug formulations and delivery systems in Austria, Germany, and Switzerland. Its pipeline includes BNT23001 for multiple sclerosis and myasthenia gravis, BNT24002 for lupus nephritis, BNT24003 for rheumatoid arthritis, BNT24004 for longevity and anti-aging, BNT24005 for solid organ transplantation, and BNT24006, an oncology drug targeting a chemotherapy platform and anticancer mTOR inhibitor. The company also offers diagnostic and biosensor screening tests, transdermal patches, and oral dissolvable formulations, and is developing psychedelic medicine for mental health conditions such as depression, anxiety, addiction, and trauma-related stress disorder. Formerly XPhyto Therapeutics Corp., it changed its name to BioNxt Solutions Inc. in November 2022, was incorporated in 2017, and is headquartered in Vancouver, Canada.